New hope for tough lymphoma: drug cocktail shows promise
NCT ID NCT05267054
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tested a new drug called ociperlimab combined with either tislelizumab or rituximab in 53 people whose diffuse large B-cell lymphoma had returned or stopped responding to treatment. The main goal was to check safety and find the right dose. Researchers also looked at whether the tumors shrank. The study is complete, but results are not yet published.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ociperlimab, Tislelizumab, Rituximab
What this could lead to
If successful, this combination could offer a new treatment option for people with hard-to-treat diffuse large B-cell lymphoma.
What could go wrong
This is an early-phase trial with only 53 participants, so results may not apply broadly. Side effects from the drug combination could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Zhongshan Hospital of Fudan University
Shanghai, Shanghai Municipality, 200032, China
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, 100050, China
-
Beijing Hospital
Beijing, Beijing Municipality, 100730, China
-
Guangdong Provincial Peoples Hospital
Guangzhou, Guangdong, 510080, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450000, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410013, China
-
Jiangxi Province Cancer Hospital
Nanchang, Jiangxi, 330029, China
-
Shandong Cancer Hospital
Jinan, Shandong, 250117, China
-
Shengjing Hospital of China Medical University
Shenyang, Liaoning, 110004, China
-
Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital
Chengdu, Sichuan, 610071, China
-
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310016, China
-
Sun Yat Sen University Cancer Center
Guangzhou, Guangdong, 510060, China
-
The First Affiliated Hospital of Nanchang University Branch Donghu
Nanchang, Jiangxi, 330006, China
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060, China
-
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
-
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, 510000, China